MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from stock
offerings, net of issuance...
$621,235K
Proceeds from exercise of
stock options
$1,119K
Net cash provided by
financing activities
$609,431K
Canceled cashflow
$12,923K
Increase (decrease) in
cash, cash...
$179,004K
Canceled cashflow
$430,427K
Payments of tax
withholdings related to...
$12,923K
Maturities of marketable
securities
$142,569K
Stock-based compensation
expense
$17,112K
Accounts payable
$6,530K
Prepaid expenses and
other current assets
-$672K
Non-cash operating lease
expense
$197K
Depreciation expense
$39K
Net cash used in
investing activities
-$344,275K
Net cash used in
operating activities
-$86,152K
Canceled cashflow
$142,569K
Canceled cashflow
$24,550K
Other income, net
$13,299K
Purchases of marketable
securities
$486,782K
Net loss
-$92,561K
Purchases of property and
equipment
$62K
Canceled cashflow
$13,299K
Accrued expenses
-$17,385K
Amortization of premiums and
discounts on marketable...
$655K
Operating lease
liabilities
-$101K
Program-specific
expenses-Vormatrigine
$20,494K
Program-specific
expenses-Ulixacaltamide
$19,103K
Personnel-related expenses
$17,730K
Stock-based compensation
expense
$17,112K
Program-specific
expenses-Relutrigine
$12,854K
Other segment
expenses
$12,089K
Program-specific expenses-Other
Early State Assets
$3,242K
Program-specific
expenses-Elsunersen
$3,197K
Depreciation expense
$39K
Back
Back
Cash Flow
source: myfinsight.com
Praxis Precision Medicines, Inc. (PRAX)
Praxis Precision Medicines, Inc. (PRAX)